Literature DB >> 35376964

[Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer].

Thomas Seufferlein1, Christoph Michalski2.   

Abstract

Pancreatic cancer still has a very unfavorable prognosis. This is true even for the comparably small group of patients (maximum 15%) who are diagnosed with a clearly resectable tumor. The article provides information on the current statements of the S3 guidelines on adjuvant and neoadjuvant treatment of resectable pancreatic cancer and describes adjuvant and neoadjuvant treatment strategies. Furthermore, the article pursues the questions of if and for whom a total neoadjuvant treatment is suitable and which options of a personalized treatment are available for resectable pancreatic cancer.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Personalized treatment; Resectability pancreatic cancer; S3 guidelines; Tissue diagnosis; Treatment protocol

Mesh：

Year:  2022        PMID： 35376964     DOI： 10.1007/s00104-022-01623-w

Source DB:  PubMed          Journal:  Chirurg        ISSN： 0009-4722            Impact factor:   0.955


  14 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

3.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

4.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

5.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

6.  International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.

Authors:  Shuji Isaji; Shugo Mizuno; John A Windsor; Claudio Bassi; Carlos Fernández-Del Castillo; Thilo Hackert; Aoi Hayasaki; Matthew H G Katz; Sun-Whe Kim; Masashi Kishiwada; Hirohisa Kitagawa; Christoph W Michalski; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-11-22       Impact factor: 3.996

7.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

8.  Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

Authors:  M Y V Homs; G van Tienhoven; M G Besselink; J W Wilmink; Q P Janssen; J L van Dam; B A Bonsing; H Bos; K P Bosscha; P P L O Coene; C H J van Eijck; I H J T de Hingh; T M Karsten; M B van der Kolk; G A Patijn; M S L Liem; H C van Santvoort; O J L Loosveld; J de Vos-Geelen; B M Zonderhuis; B Groot Koerkamp
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

9.  A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response.

Authors:  Alica K Beutel; Lena Schütte; Jeanette Scheible; Elodie Roger; Martin Müller; Lukas Perkhofer; Annika M T U Kestler; Johann M Kraus; Hans A Kestler; Thomas F E Barth; Johannes Lemke; Marko Kornmann; Thomas J Ettrich; Johann Gout; Thomas Seufferlein; Alexander Kleger
Journal:  Cancers (Basel)       Date:  2021-05-21       Impact factor: 6.639

10.  Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Syed A Ahmad; Mai Duong; Davendra P S Sohal; Namita S Gandhi; Muhammad Shaalan Beg; Andrea Wang-Gillam; James L Wade; Elena Gabriela Chiorean; Katherine A Guthrie; Andrew M Lowy; Philip A Philip; Howard S Hochster
Journal:  Ann Surg       Date:  2020-09-01       Impact factor: 13.787
View more
  1 in total

Review 1.  Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review.

Authors:  Robert Kubina; Kamil Krzykawski; Agata Kabała-Dzik; Robert D Wojtyczka; Ewa Chodurek; Arkadiusz Dziedzic
Journal:  Nutrients       Date:  2022-06-23       Impact factor: 6.706
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.